Pricing of pharmaceuticals is becoming a major challenge for health systems
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pricing of pharmaceuticals is becoming a major challenge for health systems
Authors
Keywords
-
Journal
BMJ-British Medical Journal
Volume -, Issue -, Pages l4627
Publisher
BMJ
Online
2020-01-14
DOI
10.1136/bmj.l4627
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Estimating the clinical cost of drug development for orphan versus non-orphan drugs
- (2019) Kavisha Jayasundara et al. Orphanet Journal of Rare Diseases
- Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
- (2019) Bishal Gyawali et al. JAMA Internal Medicine
- Contribution of NIH funding to new drug approvals 2010–2016
- (2018) Ekaterina Galkina Cleary et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia
- (2017) Steven G. Morgan et al. HEALTH POLICY
- Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen
- (2017) Viviana Giannuzzi et al. Orphanet Journal of Rare Diseases
- A global comparison of the cost of patented cancer drugs in relation to global differences in wealth
- (2017) Daniel A. Goldstein et al. Oncotarget
- Essential Medicines in the United States — Why Access Is Diminishing
- (2016) Jonathan D. Alpern et al. NEW ENGLAND JOURNAL OF MEDICINE
- Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research
- (2016) Beth Woods et al. VALUE IN HEALTH
- Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis
- (2016) Swathi Iyengar et al. PLOS MEDICINE
- Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States
- (2015) Jagpreet Chhatwal et al. ANNALS OF INTERNAL MEDICINE
- The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
- (2015) D. M. Hartung et al. NEUROLOGY
- The $2.6 Billion Pill — Methodologic and Policy Considerations
- (2015) Jerry Avorn NEW ENGLAND JOURNAL OF MEDICINE
- A Time-Trend Economic Analysis of Cancer Drug Trials
- (2015) S. Cressman et al. ONCOLOGIST
- Costs of New Treatments for Hepatitis C Infection
- (2014) Ruth Lopert et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding
- (2014) D. Cohen et al. BMJ-British Medical Journal
- A New Deal for Global Health R&D? The Recommendations of the Consultative Expert Working Group on Research and Development (CEWG)
- (2012) John-Arne Røttingen et al. PLOS MEDICINE
- The cost of drug development: A systematic review
- (2011) Steve Morgan et al. HEALTH POLICY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now